CJC-1295 and Ipamorelin: How Growth Hormone Secretagogue Peptides Work and What the Research Shows

CJC-1295 and Ipamorelin are among the most widely discussed growth hormone secretagogue (GHS) peptides in both clinical research and the broader peptide community. Despite their popularity, the published evidence base for each is narrower than many assume. This post, part of the Peptide Register's educational reference library, examines what the peer-reviewed literature actually says about these two peptides, their mechanisms, the quality of available data, and their regulatory standing.

For readers new to peptide science, our guide on what peptides are and how they differ from proteins and hormones provides useful background.

Mechanism of Action: Two Distinct Pathways to GH Release

CJC-1295 and Ipamorelin stimulate growth hormone (GH) release through different receptor targets.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on anterior pituitary somatotroph cells, mimicking the signalling cascade that triggers GH synthesis and secretion. CJC-1295 is a modified GHRH analogue with a Drug Affinity Complex (DAC) that extends its plasma half-life to approximately 6 to 8 days. This prolonged half-life differentiates it from native GHRH, which is degraded within minutes. A version without the DAC modification, sometimes called "modified GRF 1-29" or "CJC-1295 no DAC," has a much shorter half-life and is pharmacokinetically distinct.

Ipamorelin is a synthetic growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a). Ipamorelin is a pentapeptide ghrelin mimetic that selectively stimulates GH release without significantly elevating cortisol or prolactin levels. This selectivity has made it a subject of interest in GHS research. Unlike other ghrelin mimetics such as GHRP-6 or GHRP-2, ipamorelin appears to produce a more specific GH pulse with fewer off-target hormonal effects, based on early clinical pharmacology studies.

Published Human Evidence: What the Studies Show

The clinical evidence base for CJC-1295 includes a small number of human trials. A 2006 study by Teichman et al. published in the Journal of Clinical Endocrinology & Metabolism examined CJC-1295 with DAC in healthy adults. CJC-1295 with DAC increased mean GH levels by 2- to 10-fold and IGF-1 levels by 1.5- to 3-fold in a dose-dependent manner in a study of healthy adults. This study enrolled only 33 subjects across multiple dose cohorts and was a single-dose pharmacokinetic and pharmacodynamic trial, not a long-term efficacy or safety study.

For ipamorelin, a phase II clinical trial examined its use for postoperative ileus recovery. Ipamorelin was studied in a phase II trial for postoperative ileus but did not meet its primary efficacy endpoint in that indication. This trial, while notable for being a controlled human study, did not advance ipamorelin toward regulatory approval for any clinical use.

There are no large-scale, long-term randomised controlled trials supporting the combined use of CJC-1295 and ipamorelin for any indication. The combination of CJC-1295 and ipamorelin lacks large-scale randomised controlled trial data for any clinical indication. Much of the interest in combining these peptides is based on theoretical pharmacological rationale rather than robust clinical evidence.

Evidence Quality and Limitations

Researchers and clinicians should note several important limitations in the available data. Most published studies on CJC-1295 and ipamorelin involve small sample sizes, short durations, and surrogate endpoints such as GH or IGF-1 levels rather than clinical outcomes. Animal studies have explored additional endpoints, but findings in animal models do not reliably translate to human efficacy or safety.

Long-term safety data for CJC-1295 and ipamorelin in humans remain limited. Reported side effects in short-term trials have included injection site reactions, flushing, headache, and transient dizziness, but the absence of long-term monitoring means that chronic risk profiles are not well characterised. For a broader discussion of what is known about peptide safety across categories, see our overview of peptide side effects, contraindications, and long-term risks.

Regulatory Status

Neither CJC-1295 nor ipamorelin is approved by the FDA for any therapeutic indication. Neither CJC-1295 nor ipamorelin holds FDA approval for any therapeutic use as of 2025. In the United States, the FDA placed CJC-1295 on its Category 1 list of substances that may not be compounded under the federal bulking exemption, restricting its availability through compounding pharmacies. Ipamorelin's regulatory status varies by jurisdiction.

In Australia, growth hormone secretagogue peptides are generally classified as Schedule 4 (prescription-only) substances under the Therapeutic Goods Administration (TGA). Access typically requires a prescription from an authorised prescriber. Our post on peptide regulation around the world provides additional jurisdiction-specific detail.

CJC-1295 appeared on the FDA's Category 1 list, which restricts compounding pharmacy access in the United States. The grey market availability of these peptides raises concerns about product quality, purity, and safety, which the Peptide Register tracks through its grey market monitoring resources.

Summary

CJC-1295 and ipamorelin operate through complementary but distinct mechanisms to stimulate GH release. The published human evidence, while demonstrating pharmacodynamic activity, is limited in scope, scale, and duration. Neither peptide is approved for clinical use in major regulatory jurisdictions. Researchers and clinicians should evaluate the existing data with appropriate caution and remain attentive to evolving regulatory developments. The Peptide Register maintains structured profiles on both peptides in its peptide database for ongoing reference.